When yeast genetic interaction partners held in common between human OPTN and ANG were validated in mammalian cells and zebrafish, MAP2K5 kinase emerged as a potential drug target for ALS therapy. The gene discussed is OPTN; the disease is amyotrophic lateral sclerosis.